| Authors: |
Zaworski P; PharmOptima, Portage, Michigan, United States of America., von Herrmann KM; Spinal Muscular Atrophy Foundation, New York, New York, United States of America., Taylor S; PharmOptima, Portage, Michigan, United States of America., Sunshine SS; Spinal Muscular Atrophy Foundation, New York, New York, United States of America., McCarthy K; Spinal Muscular Atrophy Foundation, New York, New York, United States of America., Risher N; PTC Therapeutics, South Plainfield, New Jersey, United States of America., Newcomb T; Department of Neurology, University of Utah School of Medicine, Salt Lake City, Utah, United States of America., Weetall M; PTC Therapeutics, South Plainfield, New Jersey, United States of America., Prior TW; Department of Molecular Pathology, Wexner Medical Center, Ohio State University, Columbus, Ohio, United States of America., Swoboda KJ; Department of Neurology, University of Utah School of Medicine, Salt Lake City, Utah, United States of America., Chen KS; Spinal Muscular Atrophy Foundation, New York, New York, United States of America., Paushkin S; Spinal Muscular Atrophy Foundation, New York, New York, United States of America. |